+关注
Fufulum
暂无个人介绍
IP属地：未知
9
关注
0
粉丝
0
主题
0
勋章
主贴
热门
Fufulum
2021-12-22
Good
10 Biggest Price Target Changes For Wednesday<blockquote>周三10个最大价格目标变化</blockquote>
Fufulum
2021-12-22
Good
BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>
Fufulum
2021-02-05
Ha
抱歉，原内容已删除
Fufulum
2021-02-05
Ha
抱歉，原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3570530898848203","uuid":"3570530898848203","gmtCreate":1607436875716,"gmtModify":1612576962327,"name":"Fufulum","pinyin":"fufulum","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/8b1d097fab7d70f11692f4b77dfcb430","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":9,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.26","exceedPercentage":"80.16%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.62%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":691664928,"gmtCreate":1640185209764,"gmtModify":1640185209855,"author":{"id":"3570530898848203","authorId":"3570530898848203","name":"Fufulum","avatar":"https://static.tigerbbs.com/8b1d097fab7d70f11692f4b77dfcb430","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570530898848203","authorIdStr":"3570530898848203"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691664928","repostId":"1188142807","repostType":4,"repost":{"id":"1188142807","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640181395,"share":"https://www.laohu8.com/m/news/1188142807?lang=zh_CN&edition=full","pubTime":"2021-12-22 21:56","market":"us","language":"en","title":"10 Biggest Price Target Changes For Wednesday<blockquote>周三10个最大价格目标变化</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1188142807","media":"Benzinga","summary":"Barclays lifted the price target on FactSet Research Systems Inc. from $450 to $550. FactSet Researc","content":"<p><ul> <li>Barclays lifted the price target on <b>FactSet Research Systems Inc.</b> from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.</li> <li>HC Wainwright & Co. raised the price target on <b>Chimerix, Inc.</b> from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.</li> <li>Bernstein raised <b>PACCAR Inc</b> price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.</li> <li>Jefferies cut <b>Adagio Therapeutics, Inc.</b> price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.</li> <li>Barclays boosted the price target for <b>NIKE, Inc.</b> from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.</li> <li>Needham lowered the price target on <b>Cognyte Software Ltd.</b> from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.</li> <li>Jefferies cut <b>ALX Oncology Holdings Inc.</b> price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.</li> <li>Bernstein reduced the price target for <b>AGCO Corporation</b> from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.</li> <li>RBC Capital raised <b>Consolidated Edison, Inc.</b> price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.</li> <li>Oppenheimer cut <b>Biogen Inc.</b> price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.</li> </ul></p><p><blockquote><ul><li>巴克莱上调目标价<b>FactSet研究系统公司。</b>从450美元到550美元。FactSet Research股价在盘前交易中上涨1.1%，至479.89美元。</li><li>HC Wainwright&Co.上调目标价<b>奇梅里克斯公司。</b>从21美元到24美元。Chimerix股价在盘前交易中上涨4.4%至6.42美元。</li><li>伯恩斯坦提出<b>帕卡尔公司</b>目标价为94美元至98美元。PACCAR股价在盘前交易中上涨0.8%至84.04美元。</li><li>杰弗里斯削减<b>柔板治疗公司。</b>目标价为46美元至10美元。Adagio Therapeutics股价在盘前交易中下跌7.3%至9.54美元。</li><li>巴克莱提高了目标价<b>耐克公司。</b>从185美元到195美元。耐克股价在盘前交易中上涨0.2%，至166.98美元。</li><li>Needham将目标价下调至<b>科尼特软件有限公司。</b>从36美元到19美元。Cognyte Software股价在盘前交易中下跌1%，至15.54美元。</li><li>杰弗里斯削减<b>ALX肿瘤控股公司。</b>目标价为65美元至25美元。ALX Oncology Holdings股价在盘前交易中下跌1.5%至22.57美元。</li><li>伯恩斯坦降低了目标价<b>AGCO公司</b>从177美元到127美元。爱科股价在盘前交易中下跌1%，至112.95美元。</li><li>加拿大皇家银行筹集的资金<b>联合爱迪生公司。</b>目标价为78美元至85美元。联合爱迪生公司股价周二下跌0.8%，收于83.37美元。</li><li>奥本海默切<b>百健公司。</b>目标价从390美元到350美元。Biogen股价在盘前交易中下跌0.1%，至234.50美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Wednesday<blockquote>周三10个最大价格目标变化</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Wednesday<blockquote>周三10个最大价格目标变化</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-22 21:56</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><ul> <li>Barclays lifted the price target on <b>FactSet Research Systems Inc.</b> from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.</li> <li>HC Wainwright & Co. raised the price target on <b>Chimerix, Inc.</b> from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.</li> <li>Bernstein raised <b>PACCAR Inc</b> price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.</li> <li>Jefferies cut <b>Adagio Therapeutics, Inc.</b> price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.</li> <li>Barclays boosted the price target for <b>NIKE, Inc.</b> from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.</li> <li>Needham lowered the price target on <b>Cognyte Software Ltd.</b> from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.</li> <li>Jefferies cut <b>ALX Oncology Holdings Inc.</b> price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.</li> <li>Bernstein reduced the price target for <b>AGCO Corporation</b> from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.</li> <li>RBC Capital raised <b>Consolidated Edison, Inc.</b> price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.</li> <li>Oppenheimer cut <b>Biogen Inc.</b> price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.</li> </ul></p><p><blockquote><ul><li>巴克莱上调目标价<b>FactSet研究系统公司。</b>从450美元到550美元。FactSet Research股价在盘前交易中上涨1.1%，至479.89美元。</li><li>HC Wainwright&Co.上调目标价<b>奇梅里克斯公司。</b>从21美元到24美元。Chimerix股价在盘前交易中上涨4.4%至6.42美元。</li><li>伯恩斯坦提出<b>帕卡尔公司</b>目标价为94美元至98美元。PACCAR股价在盘前交易中上涨0.8%至84.04美元。</li><li>杰弗里斯削减<b>柔板治疗公司。</b>目标价为46美元至10美元。Adagio Therapeutics股价在盘前交易中下跌7.3%至9.54美元。</li><li>巴克莱提高了目标价<b>耐克公司。</b>从185美元到195美元。耐克股价在盘前交易中上涨0.2%，至166.98美元。</li><li>Needham将目标价下调至<b>科尼特软件有限公司。</b>从36美元到19美元。Cognyte Software股价在盘前交易中下跌1%，至15.54美元。</li><li>杰弗里斯削减<b>ALX肿瘤控股公司。</b>目标价为65美元至25美元。ALX Oncology Holdings股价在盘前交易中下跌1.5%至22.57美元。</li><li>伯恩斯坦降低了目标价<b>AGCO公司</b>从177美元到127美元。爱科股价在盘前交易中下跌1%，至112.95美元。</li><li>加拿大皇家银行筹集的资金<b>联合爱迪生公司。</b>目标价为78美元至85美元。联合爱迪生公司股价周二下跌0.8%，收于83.37美元。</li><li>奥本海默切<b>百健公司。</b>目标价从390美元到350美元。Biogen股价在盘前交易中下跌0.1%，至234.50美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PCAR":"帕卡","ALXO":"ALX Oncology Holdings","CMRX":"Chimerix Inc.","NKE":"耐克","CGNT":"Cognyte Software Ltd.","ED":"爱迪生联合电气","BIIB":"渤健公司","FDS":"辉盛研究系统","AGCO":"爱科集团"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188142807","content_text":"Barclays lifted the price target on FactSet Research Systems Inc. from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.\nHC Wainwright & Co. raised the price target on Chimerix, Inc. from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.\nBernstein raised PACCAR Inc price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.\nJefferies cut Adagio Therapeutics, Inc. price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.\nBarclays boosted the price target for NIKE, Inc. from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.\nNeedham lowered the price target on Cognyte Software Ltd. from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.\nJefferies cut ALX Oncology Holdings Inc. price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.\nBernstein reduced the price target for AGCO Corporation from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.\nRBC Capital raised Consolidated Edison, Inc. price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.\nOppenheimer cut Biogen Inc. price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.","news_type":1,"symbols_score_info":{"AGCO":0.9,"PCAR":0.9,"ED":0.9,"CGNT":0.9,"CMRX":0.9,"NKE":0.9,"FDS":0.9,"BIIB":0.9,"ALXO":0.9,"ADGI":0.9}},"isVote":1,"tweetType":1,"viewCount":2078,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691665587,"gmtCreate":1640185187897,"gmtModify":1640185187897,"author":{"id":"3570530898848203","authorId":"3570530898848203","name":"Fufulum","avatar":"https://static.tigerbbs.com/8b1d097fab7d70f11692f4b77dfcb430","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570530898848203","authorIdStr":"3570530898848203"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691665587","repostId":"1165830356","repostType":4,"repost":{"id":"1165830356","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640183188,"share":"https://www.laohu8.com/m/news/1165830356?lang=zh_CN&edition=full","pubTime":"2021-12-22 22:26","market":"us","language":"en","title":"BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1165830356","media":"Benzinga","summary":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the Univers","content":"<p><b>BiondVax Pharmaceuticals Ltd</b> has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul> <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li> <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li> <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.</li> <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li> <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li> <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li> <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li> <li><b>Price Action:</b> BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-22 22:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>BiondVax Pharmaceuticals Ltd</b> has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul> <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li> <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li> <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.</li> <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li> <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li> <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li> <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li> <li><b>Price Action:</b> BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165830356","content_text":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.\n\nThe parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.\nVHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).\nThese include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.\nThe collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.\nThe candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.\nBiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.\nThe parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.\nPrice Action: BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.","news_type":1,"symbols_score_info":{"BVXV":0.9}},"isVote":1,"tweetType":1,"viewCount":1990,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":380214888,"gmtCreate":1612540528544,"gmtModify":1703763478385,"author":{"id":"3570530898848203","authorId":"3570530898848203","name":"Fufulum","avatar":"https://static.tigerbbs.com/8b1d097fab7d70f11692f4b77dfcb430","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570530898848203","authorIdStr":"3570530898848203"},"themes":[],"htmlText":"Ha","listText":"Ha","text":"Ha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/380214888","repostId":"1132260998","repostType":4,"isVote":1,"tweetType":1,"viewCount":1287,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":380215954,"gmtCreate":1612540446878,"gmtModify":1703763476158,"author":{"id":"3570530898848203","authorId":"3570530898848203","name":"Fufulum","avatar":"https://static.tigerbbs.com/8b1d097fab7d70f11692f4b77dfcb430","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570530898848203","authorIdStr":"3570530898848203"},"themes":[],"htmlText":"Ha","listText":"Ha","text":"Ha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/380215954","repostId":"1132260998","repostType":4,"isVote":1,"tweetType":1,"viewCount":2050,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":380214888,"gmtCreate":1612540528544,"gmtModify":1703763478385,"author":{"id":"3570530898848203","authorId":"3570530898848203","name":"Fufulum","avatar":"https://static.tigerbbs.com/8b1d097fab7d70f11692f4b77dfcb430","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570530898848203","idStr":"3570530898848203"},"themes":[],"htmlText":"Ha","listText":"Ha","text":"Ha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/380214888","repostId":"1132260998","repostType":4,"isVote":1,"tweetType":1,"viewCount":1287,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":691664928,"gmtCreate":1640185209764,"gmtModify":1640185209855,"author":{"id":"3570530898848203","authorId":"3570530898848203","name":"Fufulum","avatar":"https://static.tigerbbs.com/8b1d097fab7d70f11692f4b77dfcb430","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570530898848203","idStr":"3570530898848203"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691664928","repostId":"1188142807","repostType":4,"repost":{"id":"1188142807","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640181395,"share":"https://www.laohu8.com/m/news/1188142807?lang=zh_CN&edition=full","pubTime":"2021-12-22 21:56","market":"us","language":"en","title":"10 Biggest Price Target Changes For Wednesday<blockquote>周三10个最大价格目标变化</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1188142807","media":"Benzinga","summary":"Barclays lifted the price target on FactSet Research Systems Inc. from $450 to $550. FactSet Researc","content":"<p><ul> <li>Barclays lifted the price target on <b>FactSet Research Systems Inc.</b> from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.</li> <li>HC Wainwright & Co. raised the price target on <b>Chimerix, Inc.</b> from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.</li> <li>Bernstein raised <b>PACCAR Inc</b> price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.</li> <li>Jefferies cut <b>Adagio Therapeutics, Inc.</b> price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.</li> <li>Barclays boosted the price target for <b>NIKE, Inc.</b> from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.</li> <li>Needham lowered the price target on <b>Cognyte Software Ltd.</b> from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.</li> <li>Jefferies cut <b>ALX Oncology Holdings Inc.</b> price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.</li> <li>Bernstein reduced the price target for <b>AGCO Corporation</b> from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.</li> <li>RBC Capital raised <b>Consolidated Edison, Inc.</b> price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.</li> <li>Oppenheimer cut <b>Biogen Inc.</b> price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.</li> </ul></p><p><blockquote><ul><li>巴克莱上调目标价<b>FactSet研究系统公司。</b>从450美元到550美元。FactSet Research股价在盘前交易中上涨1.1%，至479.89美元。</li><li>HC Wainwright&Co.上调目标价<b>奇梅里克斯公司。</b>从21美元到24美元。Chimerix股价在盘前交易中上涨4.4%至6.42美元。</li><li>伯恩斯坦提出<b>帕卡尔公司</b>目标价为94美元至98美元。PACCAR股价在盘前交易中上涨0.8%至84.04美元。</li><li>杰弗里斯削减<b>柔板治疗公司。</b>目标价为46美元至10美元。Adagio Therapeutics股价在盘前交易中下跌7.3%至9.54美元。</li><li>巴克莱提高了目标价<b>耐克公司。</b>从185美元到195美元。耐克股价在盘前交易中上涨0.2%，至166.98美元。</li><li>Needham将目标价下调至<b>科尼特软件有限公司。</b>从36美元到19美元。Cognyte Software股价在盘前交易中下跌1%，至15.54美元。</li><li>杰弗里斯削减<b>ALX肿瘤控股公司。</b>目标价为65美元至25美元。ALX Oncology Holdings股价在盘前交易中下跌1.5%至22.57美元。</li><li>伯恩斯坦降低了目标价<b>AGCO公司</b>从177美元到127美元。爱科股价在盘前交易中下跌1%，至112.95美元。</li><li>加拿大皇家银行筹集的资金<b>联合爱迪生公司。</b>目标价为78美元至85美元。联合爱迪生公司股价周二下跌0.8%，收于83.37美元。</li><li>奥本海默切<b>百健公司。</b>目标价从390美元到350美元。Biogen股价在盘前交易中下跌0.1%，至234.50美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Wednesday<blockquote>周三10个最大价格目标变化</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Wednesday<blockquote>周三10个最大价格目标变化</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-22 21:56</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><ul> <li>Barclays lifted the price target on <b>FactSet Research Systems Inc.</b> from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.</li> <li>HC Wainwright & Co. raised the price target on <b>Chimerix, Inc.</b> from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.</li> <li>Bernstein raised <b>PACCAR Inc</b> price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.</li> <li>Jefferies cut <b>Adagio Therapeutics, Inc.</b> price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.</li> <li>Barclays boosted the price target for <b>NIKE, Inc.</b> from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.</li> <li>Needham lowered the price target on <b>Cognyte Software Ltd.</b> from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.</li> <li>Jefferies cut <b>ALX Oncology Holdings Inc.</b> price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.</li> <li>Bernstein reduced the price target for <b>AGCO Corporation</b> from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.</li> <li>RBC Capital raised <b>Consolidated Edison, Inc.</b> price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.</li> <li>Oppenheimer cut <b>Biogen Inc.</b> price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.</li> </ul></p><p><blockquote><ul><li>巴克莱上调目标价<b>FactSet研究系统公司。</b>从450美元到550美元。FactSet Research股价在盘前交易中上涨1.1%，至479.89美元。</li><li>HC Wainwright&Co.上调目标价<b>奇梅里克斯公司。</b>从21美元到24美元。Chimerix股价在盘前交易中上涨4.4%至6.42美元。</li><li>伯恩斯坦提出<b>帕卡尔公司</b>目标价为94美元至98美元。PACCAR股价在盘前交易中上涨0.8%至84.04美元。</li><li>杰弗里斯削减<b>柔板治疗公司。</b>目标价为46美元至10美元。Adagio Therapeutics股价在盘前交易中下跌7.3%至9.54美元。</li><li>巴克莱提高了目标价<b>耐克公司。</b>从185美元到195美元。耐克股价在盘前交易中上涨0.2%，至166.98美元。</li><li>Needham将目标价下调至<b>科尼特软件有限公司。</b>从36美元到19美元。Cognyte Software股价在盘前交易中下跌1%，至15.54美元。</li><li>杰弗里斯削减<b>ALX肿瘤控股公司。</b>目标价为65美元至25美元。ALX Oncology Holdings股价在盘前交易中下跌1.5%至22.57美元。</li><li>伯恩斯坦降低了目标价<b>AGCO公司</b>从177美元到127美元。爱科股价在盘前交易中下跌1%，至112.95美元。</li><li>加拿大皇家银行筹集的资金<b>联合爱迪生公司。</b>目标价为78美元至85美元。联合爱迪生公司股价周二下跌0.8%，收于83.37美元。</li><li>奥本海默切<b>百健公司。</b>目标价从390美元到350美元。Biogen股价在盘前交易中下跌0.1%，至234.50美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PCAR":"帕卡","ALXO":"ALX Oncology Holdings","CMRX":"Chimerix Inc.","NKE":"耐克","CGNT":"Cognyte Software Ltd.","ED":"爱迪生联合电气","BIIB":"渤健公司","FDS":"辉盛研究系统","AGCO":"爱科集团"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188142807","content_text":"Barclays lifted the price target on FactSet Research Systems Inc. from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.\nHC Wainwright & Co. raised the price target on Chimerix, Inc. from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.\nBernstein raised PACCAR Inc price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.\nJefferies cut Adagio Therapeutics, Inc. price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.\nBarclays boosted the price target for NIKE, Inc. from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.\nNeedham lowered the price target on Cognyte Software Ltd. from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.\nJefferies cut ALX Oncology Holdings Inc. price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.\nBernstein reduced the price target for AGCO Corporation from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.\nRBC Capital raised Consolidated Edison, Inc. price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.\nOppenheimer cut Biogen Inc. price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.","news_type":1,"symbols_score_info":{"AGCO":0.9,"PCAR":0.9,"ED":0.9,"CGNT":0.9,"CMRX":0.9,"NKE":0.9,"FDS":0.9,"BIIB":0.9,"ALXO":0.9,"ADGI":0.9}},"isVote":1,"tweetType":1,"viewCount":2078,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691665587,"gmtCreate":1640185187897,"gmtModify":1640185187897,"author":{"id":"3570530898848203","authorId":"3570530898848203","name":"Fufulum","avatar":"https://static.tigerbbs.com/8b1d097fab7d70f11692f4b77dfcb430","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570530898848203","idStr":"3570530898848203"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691665587","repostId":"1165830356","repostType":4,"repost":{"id":"1165830356","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640183188,"share":"https://www.laohu8.com/m/news/1165830356?lang=zh_CN&edition=full","pubTime":"2021-12-22 22:26","market":"us","language":"en","title":"BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1165830356","media":"Benzinga","summary":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the Univers","content":"<p><b>BiondVax Pharmaceuticals Ltd</b> has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul> <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li> <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li> <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.</li> <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li> <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li> <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li> <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li> <li><b>Price Action:</b> BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-22 22:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>BiondVax Pharmaceuticals Ltd</b> has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul> <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li> <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li> <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.</li> <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li> <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li> <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li> <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li> <li><b>Price Action:</b> BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165830356","content_text":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.\n\nThe parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.\nVHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).\nThese include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.\nThe collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.\nThe candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.\nBiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.\nThe parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.\nPrice Action: BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.","news_type":1,"symbols_score_info":{"BVXV":0.9}},"isVote":1,"tweetType":1,"viewCount":1990,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":380215954,"gmtCreate":1612540446878,"gmtModify":1703763476158,"author":{"id":"3570530898848203","authorId":"3570530898848203","name":"Fufulum","avatar":"https://static.tigerbbs.com/8b1d097fab7d70f11692f4b77dfcb430","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570530898848203","idStr":"3570530898848203"},"themes":[],"htmlText":"Ha","listText":"Ha","text":"Ha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/380215954","repostId":"1132260998","repostType":4,"isVote":1,"tweetType":1,"viewCount":2050,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
